Similar Papers

Paper Title
Journal
Date
Author
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
Real-world study of lazertinib as second-line or greater treatment in advanced non-small cell lung cancer.
Jeong Uk Lim ... Seung Joon Kim
Thoracic cancer | VOL. 15
Jeong Uk Lim, et. al.Jeong Uk Lim ... Seung Joon Kim
27 May 2024
Second-Line Chemotherapy for Non-small Cell Lung Cancer
John C Ruckdeschel
Chest | VOL. 129
John C RuckdeschelJohn C Ruckdeschel
01 Apr 2006
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials
Ning Zhao ... Yi-Long Wu
Lung Cancer | VOL. 85
Ning Zhao, et. al.Ning Zhao ... Yi-Long Wu
13 Apr 2014
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
HIV Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in Non-Small Cell Lung Cancer
Baptiste Abbar ... Brigitte Autran
Journal of Thoracic Oncology | VOL. -
Baptiste Abbar, et. al.Baptiste Abbar ... Brigitte Autran
01 Feb 2025
Safety, Pharmacokinetics, and Efficacy of TY-9591 (Deuterated Osimertinib Derivative) in Advanced EGFR-mutated Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
Baohui Han ... Yusheng Wu
Journal of Thoracic Oncology | VOL. -
Baohui Han, et. al.Baohui Han ... Yusheng Wu
01 Feb 2025
Meeting Announcements
-
Journal of Thoracic Oncology | VOL. 20
--
01 Feb 2025
First-Line Camrelizumab versus Placebo Plus Chemotherapy with or without Radiotherapy for Brain Metastases in Non-Small-Cell Lung Cancer: The CTONG 2003 Randomized Placebo-Controlled Trial
Yang-Si Li ... Yi-Long Wu
Journal of Thoracic Oncology | VOL. -
Yang-Si Li, et. al.Yang-Si Li ... Yi-Long Wu
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.